Navigation Links
Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
Date:5/3/2012

o initiated a Phase 2 proof-of-concept trial of telotristat etiprate in patients with ulcerative colitis. 
  • Lexicon launched a Phase 2 trial of LX1033, a serotonin synthesis inhibitor, in patients with IBS‑d. 
  • Lexicon recently completed enrollment in a dose-ranging study to explore higher doses of LX2931, an inhibitor of sphingosine-1-phosphate lyase, in patients with rheumatoid arthritis. 
  • Lexicon initiated a Phase 1-2 proof-of-concept study of LX7101 in glaucoma patients.  LX7101 targets LIM domain kinase 2 (LIMK2), a novel mechanism of action that Lexicon research identified in preclinical models as reducing intraocular pressure by allowing more fluid to flow through the trabecular meshwork of the anterior chamber of the eye.
  • Revenues:  Lexicon's revenues for the three months ended March 31, 2012 decreased 50 percent to $0.3 million from $0.6 million for the corresponding period in 2011.  The decrease for the three months ended March 31, 2012 was primarily attributable to reduced revenues from the United States Army Medical Research Acquisition Activity and Lexicon's alliance with Taconic Farms.

    Research and Development Expenses:  Research and development expenses for the three months ended March 31, 2012 decreased four percent to $23.0 million from $23.9 million for the corresponding period in 2011.  The decrease was primarily attributable to decreases in facility and personnel costs, partially offset by an increase in external manufacturing, clinical research and development costs.

    Increase in Fair Value of Symphony Icon Purchase Liability:  In connection with the acquisition of Symphony Icon, Lexicon made an initial estim
    '/>"/>

    SOURCE Lexicon Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Lexicon to Provide First Quarter 2012 Financial Results
    2. Lexicon Pharmaceuticals to Present at the Cowen and Company 32nd Annual Health Care Conference
    3. Lexicon Pharmaceuticals to Present at the RBC Healthcare Conference
    4. Lexicon to Report Fourth Quarter and Year End 2011 Financial Results on February 22, 2012
    5. Lexicon Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
    6. Lexicon Announces Commencement of Rights Offering to Stockholders
    7. Lexicon to Present LX4211 Clinical and Preclinical Data at Diabetes Conference
    8. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Third Quarter Results
    9. Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2011 Financial Results
    10. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
    11. Lexicon Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/15/2014)... 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: ... to the NASDAQ Biotechnology Index (NBI). The addition ... upon market open on December 22, 2014. ... track the performance of a set of NASDAQ-listed ... pharmaceutical according to the Industry Classification Benchmark. The ...
    (Date:12/15/2014)... , Dec. 15, 2014 As medical ... (Structured Product Labeling) markup language standard, content teams have ... and skills to work with the standard. Starting January ... of three webinars on the benefits and the critical ... webinars will be facilitated by Howard Shatz , ...
    (Date:12/15/2014)... BOSTON , December 15, 2014 ... and development company, is pleased to announce the grant ... States relating to its GPCR-focused drug discovery ... significantly strengthens the global patent estate covering Heptares, technologies ... The suite of patents recently granted by the US ...
    Breaking Medicine Technology:Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 3Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 4Data Conversion Laboratory Helping Life Sciences Content Producers Understand the Impact and Benefits of Structured Product Labeling 2Data Conversion Laboratory Helping Life Sciences Content Producers Understand the Impact and Benefits of Structured Product Labeling 3Heptares Extends Global Patent Protection for GPCR-Focused Drug Discovery Platform With Grant of Core Patents in the United States 2
    ... Spencer Inc. (NYSE: CSA ) announced today ... of $0.10 per common share payable on October 20, 2010 ... covers the third quarter of 2010.   ... Spencer Inc. (NYSE: CSA ) is a fully-integrated, ...
    ... Pharmaceutical Company (NYSE:  KVa/KVb) announced today that it has ... ("FDA") of the successful completion of an inspection of ... product to market.  Under the Company,s Consent Decree, successful ... facilities are expected to be required before K-V is ...
    Cached Medicine Technology:Cogdell Spencer Inc. Declares Quarterly Dividend 2K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 2K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 3K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 4K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 5K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 6K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 7K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 8
    (Date:12/15/2014)... 15, 2014 Health Dialog, a ... today that it has received Patient Oriented Accreditation ... for its Disease Management (DM) Programs for asthma, ... coronary heart disease and diabetes. This marks the ... Health Dialog’s Disease Management (DM) Programs, reaffirming Health ...
    (Date:12/15/2014)... Dallas,TX (PRWEB) December 15, 2014 The increase ... is one of the main factors which is contributing to ... used for the diagnosis and treatment of hearing loss and ... comprises of three parts - microphone, speaker and amplifier. The ... growth rate of 6.01% during the period from 2014 to ...
    (Date:12/15/2014)... December 15, 2014 In support ... bring attention to restrictive state laws that may ... on this important area of public health policy. ... Compromise the Integrity of Independent Review, contends that ... of independent peer review determinations can result in ...
    (Date:12/15/2014)... IL (PRWEB) December 15, 2014 Kenmode ... joined the firm as Director of Quality Assurance. ... managing quality systems, processes and certifications for manufacturers in ... the posts of Corporate Quality Manager at Sonoco Products ... Quality at NetCom, Inc., and Quality Assurance Manager for ...
    (Date:12/15/2014)... December 15, 2014 Following on the ... The Grass Station is gearing up for another round ... Colorado’s oldest and largest marijuana dispensaries, began the 2014 ... that ran through Thanksgiving weekend. , “We've picked ... are excited,” says Grass Station CEO and founder, Ryan ...
    Breaking Medicine News(10 mins):Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4Health News:NAIRO Calls for Higher Quality Independent Peer Review By Ending Restrictive State Laws 2Health News:Kenmode Precision Metal Stamping Appoints Abid Rashid as Director of Quality Assurance 2Health News:Colorado’s Grass Station Helps Holiday Shoppers Put Something Special under the Christmas Tree 2
    ... Call Today at 5 p.m. Eastern Time -, ... Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical ... progress and financial results,for the third quarter ended ... continued to make important progress in,developing picoplatin as ...
    ... 30 Physicians Healthcare,Management Group, Inc. (Phyhealth) (Pink ... in partnership with physicians,today announced that it has ... 30, 2008. The financials are being posted today ... its updated financials, Phyhealth expects to,qualify for the ...
    ... liver failure deaths, other risks of adverse events for ... -- The diabetes drug Avandia should be banned in ... liver failure and poses many other life-threatening risks that ... said Thursday. , The group said it has identified ...
    ... it,s not clear if the cholesterol-lowering drugs protect against ... A new study shows that men who take cholesterol-lowering ... antigen (PSA), a biomarker for prostate cancer risk. , ... drugs protect against disease however, researchers say. , But ...
    ... American Society of Nephrology (ASN) proudly announce the recipient ... was created to provide funding for young faculty to ... transition funding toward successful application for an RO1 grant. ... Torban, Assistant Professor in the Department of Medicine, Division ...
    ... Free antibiotic and pre-natal vitamin programs help millions of Meijer ... ... Oct. 30 Grand Rapids-based retailer,Meijer received the Legacy of Leadership ... The award was presented,during the 29th Annual Distinguished Service Awards luncheon ...
    Cached Medicine News:Health News:Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update 2Health News:Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update 3Health News:Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update 4Health News:Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update 5Health News:Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update 6Health News:Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update 7Health News:Phyhealth Issues 2008 Third Quarter Financial Statements 2Health News:Consumer Group Seeks FDA Ban on Avandia 2Health News:Consumer Group Seeks FDA Ban on Avandia 3Health News:Statins Lower Blood Marker for Prostate Cancer 2Health News:Halpin Foundation and the ASN announce recipient of Halpin Foundation-ASN research grant 2Health News:Meijer Honored by Michigan Primary Care Association for Leadership in Promoting Health of Michigan Residents 2Health News:Meijer Honored by Michigan Primary Care Association for Leadership in Promoting Health of Michigan Residents 3
    ... connection of two state-of-the-art progressive scan digital ... beamsplitter on your microscope. The c-mount digital ... firewire cards and receive their power directly ... optical visualization without interference or compromise. The ...
    Sony DSR-20MD is the right choice If you need digital recording capability. It accepts both s-video and composite inputs....
    ... monitoring of oxygen and carbon dioxide, originally ... in a number of different applications, including ... medicine and orthopedic surgery. TcpO2 measurements usually ... to provide a good picture. The more ...
    Derrico Perforator Drill and Enlarging Burr...
    Medicine Products: